2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2, 3-dihydro-1H-benzo[de]isoquinolin-5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity

Journal of Medicinal Chemistry

Volumn 50, Issue 17, 2007, Pages 4122-4134

  Van Quaquebeke, Eric ^a   Mahieu, Tine ^a   Dumont, Patrick ^a,b   Dewelle, Janique ^a   Ribaucour, Fabrice ^a   Simon, Gentiane ^a   Sauvage, Sébastien ^a   Gaussin, Jean François ^a   Tuti, Jérôme ^a   El Yazidi, Mohamed ^a   Van Vynckt, Frank ^a   Mijatovic, Tatjana ^a   Lefranc, Florence ^b,d   Darro, Francis ^a   Kiss, Robert ^b,c  

^a Unibioscreen SA   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c FNRS   (Belgium)

^d Belgian National Fund for Scientific Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

2,2,2 TRICHLORO N [[2 [2 (DIMETHYLAMINO)ETHYL] 1,3 DIOXO 2,3 DIHYDRO 1H BENZO[DE]ISOQUINOLIN 5 YL]CARBAMOYL]ACETAMIDE; AMONAFIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GEMCITABINE; IMIDE; NAPHTHALENE DERIVATIVE; PACLITAXEL; UNBS 3157; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST ADENOCARCINOMA; CANCER CELL; CANCER MODEL; CANCER SURVIVAL; CELL AGING; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG DOSE COMPARISON; DRUG MECHANISM; FEMALE; HUMAN; IN VIVO STUDY; INTERCALATION COMPLEX; MAXIMUM TOLERATED DOSE; MOUSE; MURINE LEUKEMIA; NONHUMAN; PANCREAS CANCER; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ACETAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CAMPTOTHECIN; CELL AGING; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; ERYTHROCYTE COUNT; FEMALE; HUMANS; IMIDES; ISOQUINOLINES; LEUKOCYTE COUNT; MAXIMUM TOLERATED DOSE; MICE; NAPHTHALIMIDES; NEOPLASM TRANSPLANTATION; PLATELET COUNT; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 34548138904     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070315q     Document Type: Article

References (64)

1. Vazquez, M. E.; Blanco, J. B.; Salvadori, S.; Trapella, C.; Argazzi, R.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H.; Negri, L.; Giannini, E.; Lattanzi, R.; Colucci, M.; Balboni, G. 6-N,N-Dimethylamino-2,3-naphthalimide: A new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J. Med. Chem. 2006, 49, 3653-3658.
2. Flores, L. V.; Staples, A. M.; Mackay, H.; Howard, C. M.; Uthe, P. B.; Sexton, J. S., 3rd.; Buchmueller, K. L.; Wilson, W. D.; O'Hare, C.; Kluza, J.; Hochhauser, D.; Hartley, J. A.; Lee, M. Synthesis and evaluation of an intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase IIalpha promoter. ChemBioChem 2006, 7, 1722-1729.
3. Niu, C. G.; Qin, P. Z.; Zeng, G. M.; Gui, X. Q.; Guan, A. L. Fluorescence sensor for water in organic solvents prepared from covalent immobilization of 4-morpholinyl-1,8-naphthalimide. Anal. Bioanal. Chem. 2007, 387, 1067-1074.
4. Pervaiz, S. Reactive oxygen-dependent production of novel photochemotherapeutic agents. FASEB J. 2001, 15, 612-617.
5. Chen, S. F.; Behrens, D. L.; Behrens, C. H.; Czerniak, P. M.; Dexter, D. L.; Dusak, B. L.; Fredericks, J. R.; Gale, K. C.; Gross, J. L.; Jiang, J. B.; et al. XB596, a promising bis-naphthalimide anticancer agent. Anticancer Drugs 1993, 4, 447-457.
6. Bousquet, P. F.; Brana, M. F.; Conlon, D.; Fitzgerald, K. M.; Perron, D.; Cocchiaro, C.; Miller, R.; Moran, M.; George, J.; Quian, X. D.; et al. Preclinical evaluation of LU79553: A novel bis-naphthalimide with potent antitumor activity. Cancer Res. 1995, 55, 1176-1180.
7. Bailly, C.; Qu, X.; Chaires, J. B.; Colson, P.; Houssier, C.; Ohkubo, M.; Nishimura, S.; Yoshinari, T. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase 1 inhibition activities. J. Med. Chem. 1999, 42, 2927-2935.
8. Li, Z.; Yang, Q.; Qian, X. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: Effects of intercalation, side chains, and substituent groups. Bioorg. Med. Chem. 2005, 13, 4864-4870.
9. Noel, G.; Godon, C.; Fernet, M.; Giocanti, N.; Megnin-Chanet, F.; Favaudon, V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol. Cancer Ther. 2006, 5, 564-574.
10. Thompson, J.; Pratt, C. B.; Stewart, C. F.; Avery, L.; Bowman, L.; Zamboni, W. C.; Pappo, A. Phase I study of DMP840 in pediatric patients with refractory solid tumors. Invest. New Drugs 1999, 16, 45-49.
11. Andersson, B. S.; Beran, M.; Bakic, M.; Silberman, L. E.; Newman, R. A.; Zwelling, L. A. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987, 47, 1040-1044.
12. Hsiang, Y. H.; Jiang, J. B.; Liu, L. F. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol. Pharmacol. 1989, 36, 371-376.
13. Bear, S.; Remers, W. A. Computer simulation of the binding of amonafide and azonafide to DNA. J. Comput.-Aided Mol. Des. 1996, 10, 165-175.
14. Wang, H.; Mao, Y.; Zhou, N.; Hu, T.; Hsieh, T. S.; Liu, L. F. Atp-bound topoisomerase II as a target for antitumor drugs. J. Biol. Chem. 2001, 276, 15990-15995.
15. Scheithauer, W.; Dittrich, C.; Kornek, G.; Haider, K.; Linkesch, W.; Gisslinger, H.; Depisch, D. Phase II study of amonafide in advanced breast cancer. Breast Cancer Res. Treat. 1991, 20, 63-67.
16. Costanza, M. E.; Berry, D.; Henderson, I. C.; Ratain, M. J.; Wu, K.; Shapiro, C.; Duggan, D.; Kalra, J.; Berkowitz, I.; Lyss, A. P. Amonafide: an active agent in the treatment of previously untreated advanced breast cancer. A cancer and leukemia group B study (CALGB8642). Clin. Cancer Res. 1995, 1, 699-704.
17. O'Dwyer, P. J.; Paul, A. R.; Hudes, G. R.; Walczak, J.; Ozols, R. F.; Comis, R. L. Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer. Invest. New Drugs 1991, 9, 65-67.
18. Linke, K.; Pazdur, R.; Abbruzzese, J. L.; Ajani, J. A.; Winn, R.; Bradof, J. E.; Daugherty, K.; Levin, B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest. New Drugs 1991, 9, 353-356.
19. Perez, R. P.; Nash, S. L.; Ozols, R. F.; Comis, R. L.; O'Dwyer, P. J. Phase II study of amonafide in advanced and recurrent sarcoma patients. Invest. New Drugs 1992, 10, 99-101.
20. Malviya, V. K.; Liu, P. Y.; Alberts, D. S.; Surwit, E. A.; Craig, J. B.; Hannigan, E. V. Evaluation of amonafide in cervical cancer, phase II. A SWOG study. Am. J. Clin. Oncol. 1992, 15, 41-44.
21. Gallion, H. H.; Liu, P. Y.; Alberts, D. E.; O'Toole, R. V.; O'Sullivan, J.; Mills, G.; Smith, H. O.; Hynes, H. E. Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study. Gynecol. Oncol. 1992, 46, 230-232.
22. Felder, T. B.; McLean, M. A.; Vestal, M. L.; Lu, K.; Farquhar, D.; Legha, S. S.; Shah, R.; Newman, R. A. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug Metab. Dispos. 1987, 15, 773-778.
23. Ratain, M. J.; Mick, R.; Berezin, F.; Janisch, L.; Schilsky, R. L.; Vogelzang, N. J.; Lane, L. B. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993, 53, 2304-2308.
24. Ratain, M. J.; Mick, R.; Berezin, F.; Janisch, L.; Schilsky, R. L.; Williams, S. F.; Smiddy, J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin. Pharmacol. Ther. 1991, 50, 573-579.
25. Ratain, M. J.; Rosner, G.; Allen, S. L.; Costanza, M.; Van Echo, D. A.; Henderson, I. C.; Schilsky, R. L. Population pharmacodynamic study of amonafide: A cancer and leukemia group B study. J. Clin. Oncol. 1995, 13, 741-747.
26. Van Quaquebeke, E.; Simon, G.; van den Hove, L.; Kiss, R.; Darro, F. Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom. Patents EP2004/447114.2; US60/558.469; PCT/BE2005/000069; WO2005/105753.
27. Kiss, R.; de Launoit, Y.; Danguy, A.; Paridaens, R.; Pasteels, J. L. Influence of pituitary grafts or prolactin administrations on the hormone sensitivity of ovarian hormone-independent mouse mammary MXT tumors. Cancer Res. 1989, 49, 2945-2951.
28. Darro, F.; Decaestecker, C.; Gaussin, J. F.; Mortier, S.; Van Ginckel, R.; Kiss, R. Are syngeneoic mouse tumor models still valuable experimental models in the field of anticancer drug discovery? Int. J. Oncol. 2005, 27, 607-616.
29. Kraus-Berthier, L.; Jan, M.; Guilbaud, N.; Naze, M.; Pierre, A.; Atassi, G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin. Cancer Res. 2000, 6, 297-304.
30. Mathieu, A.; Remmelink, M.; D'Haene, N.; Penant, S.; Gaussin, J. F.; Van Ginckel, R.; Darro, F.; Kiss, R.; Salmon, I. Development of a chemoresistant orthotopic human non-small cell lung carcinoma model in nude mice. Cancer 2004, 101, 1908-1918.
31. De Isabelle, P.; Zunino, F.; Capranico, G. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage. Nucleic Acids Res. 1995, 23, 223-229.
32. Zhu, H.; Huang, M.; Yang, F.; Chen, Y.; Miao, Z. H.; Qian, X. H.; Xu, Y. F.; Qin, Y. X.; Luo, H. B.; Shen, X.; Geng, M. Y.; Cai, Y. J.; Ding, J. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol. Cancer Ther. 2007, 6, 484-495.
33. Pourpak, A.; Landowski, T. H.; Dorr, R. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J. Pharmacol. Exp. Ther. 2007, 321 (3), 1109-1117.
34. Mayr, C. A.; Sami, S. M.; Dorr, R. T. In vitro cytotoxicity and DNA damage production in Chinese hamster ovary cells and topoisomerase II inhibition by 2-[2′-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-[de,h] isoquinoline-1,3-diones with substitutions at the 6 and 7 positions (azonafides). Anticancer Drugs 1997, 8, 245-256.
35. Nitiss, J. L.; Zhou, J.; Rose, A.; Hsiung, Y.; Gale, K. C.; Osheroff, N. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II. Biochemistry 1998, 37, 3078-3085.
36. Giles, G. I.; Sharma, R. P. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem. 2005, 1, 383-394.
37. Gong, Y.; Firestone, G. L.; Bjeldanes, L. F. 3,3′-diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells. Mol. Pharmacol. 2006, 69, 1320-1327.
38. Zhao, R.; Domann, F. E.; Zhong, W. Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol. Cancer Ther. 2006, 5, 3275-3284.
39. Li, G. X.; Hu, H.; Jiang, C.; Schuster, T.; Lu, J. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int. J. Cancer 2007, 120, 2034-2043.
40. Pratt, M. A.; White, D.; Kushwaha, N.; Tibbo, E.; Niu, M. Y. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells. Apoptosis 2007, 12, 657-669.
41. Kroemer, G.; Jäättelä, M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 2005, 5, 886-897.
42. Kondo, Y.; Kanzawa, T.; Sawaya, R.; Kondo, S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 2005, 5, 726-734.
43. Kanzawa, T.; Germano, I. M.; Komata, T.; Ito, H.; Kondo, Y.; Kondo, S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004, 11, 448-457.
44. Okada, H.; Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4, 592-603.
45. Dimri, G. P.; Lee, X.; Basile, G.; Acosta, M.; Scott, G.; Roskelley, C.; Medrano, E. E.; Linskens, M.; Rubell, I.; Pereira-Smith, O.; Peacocke, M.; Campisi, J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 9363-9367.
46. Campisi, J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 2005, 120, 513-522.
47. Chang, B. D.; Broude, E. V.; Dokmanovic, M.; Zhu, H.; Ruth, A.; Xuan, Y.; Kandel, E. S.; Lausch, E.; Christov, K.; Roninson, I. B. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999, 59, 3761-3767.
48. Brana, M. F.; Ramos, A. Naphthalimides as anti-cancer agents: Synthesis and biological activity. Curr. Med. Chem. Anticancer Agents 2001, 1, 237-255.
49. Brana, M. F.; Cacho, M.; Garcia, M. A.; de Pascual-Teresa, B.; Ramos, A.; Acero, N.; Llinares, F.; Munoz-Mingarro, D.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M. Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides. J. Med. Chem. 2002, 45, 5813-5816.
50. Bailly, C.; Carrasco, C.; Joubert, A.; Bal, C.; Wattez, N.; Hildebrand, M. P.; Lansiaux, A.; Colson, P.; Houssier, C.; Cacho, M.; Ramos, A.; Brana, M. F. Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides. Biochemistry 2003, 42, 4136-4150.
51. Brana, M. F.; Cacho, M.; Ramos, A.; Dominguez, M. T.; Pozuelo, J. M.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M.; Carrasco, C.; Bailly, C. Synthesis, biological evaluation and DNA binding properties of novel mono and bisnaphthalimides. Org. Biomol. Chem. 2003, 1, 648-654.
52. Brana, M. F.; Cacho, M.; Garcia, M. A.; de Pascual-Teresa, B.; Ramos, A.; Dominguez, M. T.; Pozuelo, J. M.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M.; Banez-Coronel, M.; Lacal, J. C. New analogues of amonafide and elinafide, containing aromatic heterocycles: Synthesis, antitumor activity, molecular modeling, and DNA binding properties. J. Med. Chem. 2004, 47, 1391-1399.
53. Lefranc, F; Kiss, R. Autophagy, the Trojan horse to combat glioblastomas. Neurosurg. Focus 2006, 20, E7.
54. Lefanc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 2005, 23, 2411-2422.
55. Mathieu, V.; Le Mercier, M.; De Neve, N.; Sauvage, S.; Gras, T.; Roland, I.; Lefranc, F.; Kiss, R. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J. Invest. Dermatol. 2007, in press.
56. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
57. Giovannetti, E.; Mey, V.; Nannizzi, S.; Pasqualetti, G.; Del Tacca, M.; Danesi, R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther. 2006, 5, 1387-1395.
58. Westphal, S.; Kalthoff, H. Apoptosis: Targets in pancreatic cancer. Mol. Cancer 2003, 2, 6.
59. Joseph, B.; Darro, F.; Behard, A.; Lesur, B.; Collignon, F.; Decaestecker, C.; Frydman, A.; Guillaumet, G.; Kiss, R. 3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration. J. Med. Chem. 2002, 45, 2543-2555.
60. Delfourne, E.; Darro, F.; Portefaix, I.; Galaup, C.; Bayssade, S.; Bouteillé, A.; Le Corre, L.; Bastide, J.; Collignon, F.; Lesur, B.; Frydman, A.; Kiss, R. Synthesis and in vitro antitumor activity of novel ring D analogues of the marine pyridoacridine ascididemin: Structure-activity relationship. J. Med. Chem. 2002, 45, 3765-3771.
61. Van Quaquebeke, E.; Simon, G.; Andre, A.; Dewelle, J.; Yazidi, M. E.; Bruyneel, F.; Tuti, J.; Nacoulma, O.; Guissou, P.; Decaestecker, C.; Braekman, J. C.; Kiss, R.; Darro, F. Identification of a novel cardenolide (2″-oxovorusharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: Structure-activity relationship analyses. J. Med. Chem. 2005, 48, 849-856.
62. Ingrassia, L.; Nshimyumukiza, P.; Dewelle, J.; Lefranc, F.; Wlodarczak, L.; Thomas, S.; Dielie, G.; Chiron, C.; Zedde, C.; Tisnès, P.; van Soest, R.; Braeckman, J. C.; Darro, F.; Kiss, R. A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. J. Med. Chem. 2006, 49, 1800-1807.
63. Lesueur-Ginot, L.; Demarquay, D.; Kiss, R.; Kasprzyk, P. G.; Dassonneville, L.; Bailly, C.; Camara, J.; Lavergne, O.; Bigg, D. C. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res. 1999, 59, 2939-2943.
64. Mijatovic, T.; Op De Beeck, A.; Van Quaquebeke, E.; Dewelle, J.; Darro, F.; de Launoit, Y.; Kiss, R. The cardenolide UNBS1450 is able to deactivate nuclear factor-kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol. Cancer Ther. 2006, 5, 391-399.